Mesentech is developing a range of complementary approaches to clinical conditions affecting the bone.

&

BONE TARGETING

Delivery of small molecule drugs and growth factors directly to bone

  • Novel platform technology that can deliver enhanced efficacy and minimize side-effects
  • Effective targeting to bone confirmed in animal models
  • Developing products for – osteomyelitis, bone cancers and bone metastases

PRECLINICAL PROOF OF PRINCIPLE ACHIEVED

+

BONE REGENERATION

Both systemic and topical delivery

  • Pre-clinical utility confirmed in models of bone regeneration
  • Pre-clinical anabolic efficacy confirmed in models of osteoporosis and dental implants
  • Developing C3 (containing EP4a as the therapeutic) in Brittle Bone Disease; Osteoporosis; dental implants and spinal fusion

PRECLINICAL PROOF OF PRINCIPLE ACHIEVED

/

GENE SILENCING

Nano-particle delivery of siRNA forgene knockdown

  • Developing silencing of bone-related genes (e.g. SOST) for osteoporosis and bone regeneration

IN RESEARCH